Pegylated interferon as a first line treatment in polycythemia vera and essential thrombocythemia patients: a quasi-experimental study
Full Text
Share
BACKGROUND: Polycythemia vera (PV) and essential thrombocythemia (ET) are
myeloproliferative disorders that are characterized by a proliferation of the erythroid and
platelet series, respectively. These patients' survival is long and therefore drugs that are safe
and effective in the long term are needed. In this respect, pegylated interferon (peg-IFNα-2a)
is proposed as an optimal drug for first-line treatment. With the new formulations of the
molecule, the tolerability profile has improved considerably and there is evidence of
clinicohematologic and molecular responses that are not only comparable to classical
treatment (hydroxyurea), but also more sustained over time. In some cases, it is even
becoming possible to discontinue treatment without disease progression.
OBJECTIVE: The aim of this study is to evaluate the effect of peg-IFNα-2a on
clinicohematologic and molecular response, incidence of thrombotic/bleeding events and
toxicity after 24 months of treatment.
DESIGN: A multicenter ambispective quasi-experimental study has been designed.
PARTICIPANTS: Patients with PV or ET diagnosis that are candidates to receive peg-IFNα-2a
as a first line treatment in Catalan hospitals.
METHODS: Data will be obtained both retrospectively and prospectively from the medical
history of the patients and their regular visits on the Hematological departments. Statistical
representation of the variables results will also be performed through a univariate, bivariate
and multivariate analysis